Expert Advice 12 Dec 2019 Tips & Tricks for Social Media in the Life Sciences With social media, as with many industries, you have to make sure to stay on top of the game. The phrase ‘if you snooze, you lose’ remains as true as ever. If you don’t jump on the bandwagon now, you might be in for a bad surprise later. We don’t want you to miss out, […] December 12, 2019 - 14 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Expert Advice 11 Dec 2019 What Makes a Successful Biotech? How does it feel to have co-developed the most successful drug in the world? This is something Jane Osbourn, now Chair of the Board at UK cell therapy biotech Mogrify, knows only too well. Early in her career, Osbourn was working as a postdoc in Cambridge and was persuaded to join a small, and at […] December 11, 2019 - 12 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2019 €14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […] December 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2019 Collaboration Between Founders and Investors Primes Biotech Startups for Success How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […] December 11, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2019 After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction The strong placebo effect seen in Futura Medical’s phase III trial in erectile dysfunction has not deterred the company, but has instead encouraged it to seek approval for its medical device delivering the placebo rather than the drug as originally intended. Based in Surrey, UK, Futura Medical is developing a medical device used […] December 10, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2019 ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […] December 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […] December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Scientists Use DNA Data Storage to Hide Information in Everyday Objects Scientists have developed a method for storing DNA data in 3D-printed objects, which could one day allow machines to replicate themselves. The group, based at ETH Zurich, Switzerland, as well as in Israel and the US, began by synthesizing DNA molecules that encode blueprints of the Stanford bunny, a rabbit-shaped object commonly used in testing […] December 9, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2019 As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers? With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […] December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Update: Cancer Immunotherapy Biotech Files for Insolvency Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […] December 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Dutch Startup Gets €9M to Create First Lab-Grown Pork Prototype Dutch startup Meatable has raised €9M in a seed round that will allow the company to host a tasting of its first prototype of lab-grown pork by summer 2020. The fundraising was led by the German VC BlueYard Capital, which had participated in Meatable’s previous €3M round last year. New investors include business angels Albert […] December 6, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […] December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email